

Arecor Therapeutics plc
("Arecor" or the "Group")

NOTICE OF INTERIM RESULTS

Cambridge, UK, 19 September 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its Interim Results for the six months ended 30 June 2024 on Thursday 26 September 2024.

Sarah Howell, Chief Executive Officer, will host an in-person briefing for analysts at 9:30am BST on the day of the results at the offices of ICR Consilium, 85 Gresham Street, London, EC2V 7NQ. There will also be a live webcast and conference call with a Q&A session.

For more details or to attend the briefing, please contact arecor@consilium-comms.com

- ENDS -

For more information, please contact:

Arecor Therapeutics plc

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Panmure Liberum Limited (NOMAD and Joint Broker)

Freddy Crossley, Emma Earl, Mark Rogers (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0) 20 7886 2500

WG Partners LLP (Joint Broker)

Nigel Barnes, Satheesh Nadarajah

David Wilson, Claes Spang

Tel: +44 (0) 203 705 9321

ICR Consilium

Chris Gardner, David Daley, Lindsey Neville

Tel: +44 (0) 20 3709 5700

Email: arecor@consilium-comms.com

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBSGDCLBBDGSC